Navigation Links
Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
Date:5/21/2008

> enriched for the presence of EGFR mutations: Results from phase 2"

Day: Sunday, June 1

Session: Lung Cancer -- Metastatic

Time: 2-6 p.m.

Location: S Hall A1

Poster Number: 42H Abstract Number: 8053

Presenter: Naiyer A Rizvi, MD

Monday, June 2

-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion

"Activity and tolerance of XL647 in NSCLC patients with acquired

resistance to EGFR-TKIs: Preliminary results of a phase 2 trial"

Day: Monday, June 2

Session: Lung Cancer -- Metastatic

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-12:15 p.m. Location: W375d

Poster Number: 9 Abstract Number: 8028

Presenter: Vincent A. Miller, MD

-- XL880* (MET, VEGFR2) -- Poster

"Preliminary activity of GSK1363089 (XL880), a dual MET/VEGFR2

inhibitor, in MET amplified poorly differentiated gastric cancer

(PDGC): Interim results of a multicenter phase 2 study"

Day: Monday, June 2

Session: Gastrointestinal (Noncolorectal) Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 33D Abstract Number: 4572

Presenter: Minaxi P. Jhawer, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent A ... form covalent bonds with metal ions, thereby forming ... that some metal-ions have on chemical processes, formulations, ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According to ... continues to reshape the look and feel of markets ... demand for higher-quality ingredients will push for more branded, ... market have experienced strong market growth in the last ... in their food and cosmetics to fit a more ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... ... Communications and Communications Convergence , ... San Diego, CA (PRWEB) June 17, 2009 -- CommNexus and ... of unlimited wireless services, today announce their support for EvoNexus, a non-profit incubator dedicated ...
... Calif., June 17 Oclaro, Inc. (Nasdaq: ... Fluorescence Filter for biomedical and analytical instrumentation markets. Oclaro ... range of biomedical and analytical applications, including clinical diagnostics, ... The latest offerings from the Oclaro filter portfolio are ...
... BioEnergy International, LLC (BioEnergy), a ... biochemicals and biofuels, announces the formation of Myriant ... biobased chemicals business and intellectual property. BioEnergy ... its 110 million gallon per day ethanol plant ...
Cached Biology Technology:San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 2San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 3San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 4Oclaro(TM) Hits Milestone With Clarity(TM) Fluorescence Filters 2Oclaro(TM) Hits Milestone With Clarity(TM) Fluorescence Filters 3BioEnergy International, LLC Announces Formation of Myriant Technologies LLC 2
(Date:8/27/2014)... of fishing traps are lost or abandoned each year ... derelict traps, which continue to catch fish, crabs, and ... losses to habitat, fisheries, and the watermen who depend ... a newly published NOAA study. , The report, published ... first of its kind to examine the derelict fish ...
(Date:8/27/2014)... Complex of fires had consumed 24,939 acres of land ... as of eight hours ago. , Lightning strikes ... of the Klamath National Forest when a thunderstorm passed ... three of those fires are now 100 percent contained. ... their size at containment: Delta, 150 acres; Sutcliffe, 27 ...
(Date:8/26/2014)... a colony of harmful bacteria, biofilms make the ... in a biofilm pose a significant health risk ... treatment, and biofilm-protected bacteria account for some 80 ... are 50 to 1,000 times more resistant to ... we may have stumbled onto a magic bullet," ...
Breaking Biology News(10 mins):NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2Happy Camp and July Fire Complexes in California 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... and American Board of Internal Medicine (ABIM) announce the ... performance evaluation tools for blood specialists. , ... ABIM certification, ASH and ABIM have co-developed the Hematology ... to complete their practice performance assessment requirement for recertification. ...
... research project which could revolutionise the diagnosis and treatment ... four-year project, the results of which are now being ... means of identifying the two most deadly forms of ... for practitioners. , The implications for improving children's health ...
... to ferns to create a novel energy scavenging device that ... provide a method for powering micro and nano devices with ... works," said Michel Maharbiz, assistant professor of electrical engineering and ... the device. "If you build these things they will move. ...
Cached Biology News:New tool helps blood specialists improve patient care 2Hope for major advance in fighting world killer disease 2Hope for major advance in fighting world killer disease 3Ferns provide model for tiny motors powered by evaporation 2
Tachykinin (H-2)...
Human BMP 2 Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... utilizies CTI Molecular Imaging's proprietary Focus™ detector ... volume as the R4. The microPET ... any commerically avaiable PET scanner. Focus ... of any scinitallor based PETsystems. The ...
Biology Products: